The incidence of gastric cancer is increasing year by year,
clinical patients are mostly diagnosed with advanced gastric
cancer. The effect of surgical treatment is often limited, it
is necessary to be further treated with chemotherapy, but
the overall effect is still unsatisfactory. How to improve
the sensitivity of cancer cells on chemotherapy drugs and
simultaneously reduce the damage of chemotherapy drugs
on normal tissue cells has become an important research
topic. Much progress of hyperbaric oxygen on malignant
tumor treatment has been made, and the sensitization
the mechanism that hyperbaric oxygen treats malignant
tumors have been proved in the experiment, which has a
good prospect in the adjuvant therapy of malignant tumor;
however, the clinical application in gastric cancer after
the operation has not been reported. In this paper, we combined
gastric cancer postoperative with hyperbaric oxygen
therapy to explore the clinical application in postoperative
chemotherapy for advanced gastric cancer.

High prentire oxygen solution

Hyperbaric oxygen combined with chemotherapy was
performed in the experimental groups. The medical
hyperbaric oxygen chamber with pure 0, was used for
the treatment, the pressure is 2.0-2.5 absolute atmosphere
(ATA), the patient absorbed oxygen 20 min x4, and
absorbed air discontinuously 5 min x3. Hyperbaric oxygen
is absorbed five times before chemotherapy, once a day,
and then the hyperbaric oxygen and chemotherapy were
performed simultaneously. The chemotherapy was started at
15-30 min after the absorption of oxygen, the pure saturated
oxygen was absorbed for 1 hour after chemotherapy, the
hyperbaric oxygenation was continued to absorbed 10 times
and once a day during the interval chemotherapy.

All patients were completed gastric cancer
D2 radical surgery, the cases were diagnosed with gastric
cancer stage II, Ma and Mb by postoperative pathological
histology, and assessed more than 60 points with Karnofsky
Performance Status (KPS), the patients were expected to
survive more than 3 months, no more than 80 years old,
with normal blood picture, liver and kidney function,
without vital organ lesions history of other malignancies and
contraindications of chemotherapy and hyperbaric oxygen
therapy. The study was approved by the Ethics Committee
of Renji Hospital and informed consents were obtained
from all patients. There was no statistically significant
difference in general information between the two groups
of patients, as shown in Table 1.

Two groups of patients were expected to complete eight
chemotherapy periods, the imaging evaluation results
of two groups of patients in the experimental group and
the control group were compared, the upper abdominal
enhancement computed tomography (CT) were used
to evaluate tumor recurrence and enlarged lymph node
status, the changes of tumor indicators (CEA and CA199)
in two groups of chemotherapy patients were observed,
the chemotherapy adverse reaction were classified into

0 (no), I (mild), II (moderate), III (severe) and IV (heavy)
according to the W HO evaluation standard. Quality
of Life-Core 30 Questionnaire (QLQ-C30) developed
by EORTC was performed to evaluated life quality of
patients. The questionnaire was completed by the patients,